70771-1365 NDC - NIFEDIPINE

Drug Information

Product NDC: 70771-1365

Proprietary Name: NIFEDIPINE

Non Proprietary Name: NIFEDIPINE

Active Ingredient(s):
  • 30 mg/1 NIFEDIPINE

Administration Route(s): ORAL


Pharmacy Class(es):
  • Calcium Channel Antagonists [MoA];
  • Dihydropyridine Calcium Channel Blocker [EPC];
  • Dihydropyridines [CS]

Labeler Information

Labeler Name: Cadila Healthcare Limited
FDA Application Number: ANDA210184
Marketing Category: ANDA
Start Marketing Date:8/18/2018

Package Information

No. Package Code Package Description Billing Unit
170771-1365-01000 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1365-0)
270771-1365-1100 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1365-1)
370771-1365-410 BLISTER PACK in 1 CARTON (70771-1365-4) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
470771-1365-5500 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1365-5)
570771-1365-7300 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1365-7)
670771-1365-990 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1365-9)

NDC Record

Field Name Field Value Definition
PRODUCT NDC70771-1365The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMENIFEDIPINEThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMENIFEDIPINEThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMETABLET, EXTENDED RELEASEThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE8/18/2018This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEANDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERANDA210184This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMECadila Healthcare LimitedName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMENIFEDIPINEThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
PHARM CLASSESCalcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [CS] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 5/20/2020